Stockreport

MannKind Corporation (MNKD) Secures FDA Approval for FUROSCIX Pediatric Use, Expanding Reach In Heart, Kidney Disease Care [Yahoo! Finance]

MannKind Corporation  (MNKD) 
Last mannkind corporation earnings: 2/25 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.mannkindcorp.com/press-releases
PDF for the FUROSCIX On-body Infusor to treat pediatric patients weighing 43 kg or more. This expands the treatment's existing reach beyond adults with chronic heart failure [Read more]